Arcutis Biotherapeutics Presents New Caregiver-Reported Outcomes Data From INTEGUMENT-INFANT Trial Supporting ZORYVE Cream 0.05%, At ACAAI Annual Scientific Meeting

Benzinga · 20h ago
  • New INTEGUMENT-INFANT trial results demonstrate improvements in itch, reductions in symptoms, and improvements in quality of life for infants with atopic dermatitis and their families
  • Findings further support investigational ZORYVE cream 0.05% to help address unmet needs in infants aged 3 to <24 months
  • 60% of children develop atopic dermatitis symptoms within their first year of life
     

WESTLAKE VILLAGE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced new caregiver-reported outcomes data from the INTEGUMENT-INFANT trial supporting ZORYVE® (roflumilast) cream 0.05% in the treatment of infants with mild to moderate atopic dermatitis ages 3-24 months presented at the American College of Allergy, Asthma & Immunology's (ACAAI) Annual Scientific Meeting, taking place Nov. 12-16 in Phoenix, Arizona.